Mesothelin chimeric antigen receptor, mRNA and application of mesothelin chimeric antigen receptor in preparation of medicine for treating solid tumor expressing mesothelin

By using mesothelin chimeric antigen receptor (MSLN-CAR) and mRNA technology, the limitations of CAR-T cell therapy in the treatment of solid tumors have been overcome, achieving efficient and safe tumor immunotherapy. This overcomes problems such as immunosuppressive microenvironment, insufficient tumor infiltration, and off-target toxicity, providing a more controllable and safer treatment option.

CN121800939APending Publication Date: 2026-04-07SUZHOU RIKA BIOMEDICAL TECHNOLOGY CO LTD
1 Cites 0 Cited by

Patent Information

Application Number
CN202512054314.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-31
Publication Date
2026-04-07

AI Technical Summary

Technical Problem

Current CAR-T cell therapies face challenges in the treatment of solid tumors, including an immunosuppressive tumor microenvironment, insufficient CAR-T cell tumor infiltration, antigen heterogeneity and escape, off-target toxicity, and insufficient persistence, resulting in poor efficacy and high safety risks.

Method used

Using mesothelin chimeric antigen receptor (MSLN-CAR) and its encoding mRNA, T cells were efficiently transfected via a non-viral method to achieve transient expression of the CAR protein, optimize the intracellular signaling domain to activate T cells, and combine with a lipid delivery vector to improve transfection efficiency and safety.

Benefits of technology

It improves the safety and anti-tumor activity of CAR-T cells, reduces the incidence of serious side effects, simplifies the production process, reduces costs, and enhances the therapeutic effect on solid tumors.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine. The invention provides a novel, efficient and safe mesothelin chimeric antigen receptor and a coding mRNA thereof, and also provides a method for performing T cell engineering transformation by using the mesothelin chimeric antigen receptor mRNA, so as to treat tumors expressing mesothelin. According to the technical scheme, T cells are efficiently transfected in a non-virus mode, transient expression of CAR protein is achieved, and the safety of the CAR-T cells is enhanced; meanwhile, the limitation of the existing CAR-T cell therapy during solid tumor treatment is overcome, migration and infiltration of CAR T cells to tumor parts are improved, and the effect of treating solid tumors expressing MSLN is better enhanced.
Need to check novelty before this filing date? Find Prior Art